Literature DB >> 9284087

AM630 is a competitive cannabinoid receptor antagonist in the guinea pig brain.

K Hosohata1, R M Quock, Y Hosohata, T H Burkey, A Makriyannis, P Consroe, W R Roeske, H I Yamamura.   

Abstract

AM630 has been demonstrated to be a cannabinoid receptor antagonist in the mouse brain and vas deferens. Conversely, it was recently reported that AM630 acts as a cannabinoid agonist in the guinea pig ileum. This research was designed to determine whether the difference in the action of AM630 is species specific. Studies conducted in guinea pig brain reveal that AM630 antagonizes the stimulatory effect of the cannabinoid agonist WIN 55,212-2 on [35S]GTPgammaS binding suggesting that difference in AM630 activity in different tissues is not due to species variation.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9284087     DOI： 10.1016/s0024-3205(97)00596-1

Source DB:  PubMed          Journal:  Life Sci        ISSN： 0024-3205            Impact factor:   5.037


  14 in total

1.  Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630.

Authors:  R A Ross; H C Brockie; L A Stevenson; V L Murphy; F Templeton; A Makriyannis; R G Pertwee
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

2.  The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset.

Authors:  Jennifer L Shoemaker; Kathryn A Seely; Ronald L Reed; John P Crow; Paul L Prather
Journal:  J Neurochem       Date:  2007-01-04       Impact factor: 5.372

3.  Cannabinoid receptor antagonists AM251 and AM630 activate TRPA1 in sensory neurons.

Authors:  Mayur Patil; Amol Patwardhan; Margaux M Salas; Kenneth M Hargreaves; Armen N Akopian
Journal:  Neuropharmacology       Date:  2011-05-27       Impact factor: 5.250

4.  In vivo effects of CB2 receptor-selective cannabinoids on the vasculature of normal and arthritic rat knee joints.

Authors:  J J McDougall; V Yu; J Thomson
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

5.  Functional characterization of transient receptor potential channels in mouse urothelial cells.

Authors:  Wouter Everaerts; Joris Vriens; Grzegorz Owsianik; Giovanni Appendino; Thomas Voets; Dirk De Ridder; Bernd Nilius
Journal:  Am J Physiol Renal Physiol       Date:  2009-12-16

6.  Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats.

Authors:  Ronald Mathison; Winnie Ho; Quentin J Pittman; Joseph S Davison; Keith A Sharkey
Journal:  Br J Pharmacol       Date:  2004-07-12       Impact factor: 8.739

7.  Cannabinoid modulation of cutaneous Adelta nociceptors during inflammation.

Authors:  Carl Potenzieri; Thaddeus S Brink; Cholawat Pacharinsak; Donald A Simone
Journal:  J Neurophysiol       Date:  2008-09-10       Impact factor: 2.714

8.  Contribution of hypothermia and CB1 receptor activation to protective effects of TAK-937, a cannabinoid receptor agonist, in rat transient MCAO model.

Authors:  Noriko Suzuki; Motohisa Suzuki; Kazuhiro Hamajo; Koji Murakami; Tetsuya Tsukamoto; Masato Shimojo
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

9.  Cannabinoid receptors as target for treatment of osteoporosis: a tale of two therapies.

Authors:  Aymen I Idris
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

10.  Role of cannabinoids in the regulation of bone remodeling.

Authors:  Aymen I Idris; Stuart H Ralston
Journal:  Front Endocrinol (Lausanne)       Date:  2012-11-16       Impact factor: 5.555
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.